What Risks of “LOW T” Therapy have Drug Manufacturers Disclosed to the Public?
Even where an individual has been diagnosed with androgen deficiency and is a candidate for TT, it is critical that the health condition of the individual and risks of the TT are thoroughly reviewed before a prescribing decision is made. Each product label contains important information regarding: contraindications (health conditions that serve as a reason for not prescribing the TT); warnings (possible serious side effects); precautions (how to use the drug, possible drug interactions with other drugs); and adverse reactions (all side effects observed in studies of the drug). Accordingly to drug makers, common risks/reactions associated with the above TT products include:
- Increased risk of prostate cancer/prostate enlargement;
- Increased risk of hepatitis
- Gynecomastia (enlargement of male breast tissue/breast pain)
- Sleep apnea.
In May 2009, the FDA issued an order to the makers of testosterone gel products to place a “black box” warning – the FDA’s sternest warning – on their products, warning of the risks of secondary exposure after receiving numerous reports of children who were incidentally exposed. The children suffered adverse reactions such as premature development, advanced bone growth, and aggressive behavior.
Despite these warnings, studies have shown additional risks surrounding testosterone therapy, which include:
Deep Vein Thrombosis
For more information on these risks, you may contact our attorneys toll-free at 888-888-2110 or via email at firstname.lastname@example.org, or by visiting www.TestosteroneWarnings.com to order your free copy of our report, Testosterone Injury Information Revealed.